Ranibizumab treatment for neovascular age-related macular degeneration in patients with good baseline visual acuity (better than 6/12): 12-month outcomes
Intravitreal Ranibizumab (Lucentis) monotherapy is currently the standard of care for neovascular age-related macular degeneration (AMD), supported by well-conducted clinical trials and non-randomised studies. 1-4 Visual and anatomical outcomes are definitely better than Verteporfin Photodynamic the...
Gespeichert in:
Veröffentlicht in: | British journal of ophthalmology 2010-11, Vol.94 (11), p.1543-1545 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Schreiben Sie den ersten Kommentar!